These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. [Comment on R. Thomasius, M. Schmolke, D. Kraus: MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae]. Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H Fortschr Neurol Psychiatr; 1999 Dec; 67(12):574-6. PubMed ID: 10683753 [No Abstract] [Full Text] [Related]
15. [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?]. Tretter F Nervenarzt; 1997 Nov; 68(11):922-3. PubMed ID: 9732739 [No Abstract] [Full Text] [Related]
17. Methodological problems with ecstasy and the SCL-90. Cole JC; Sumnall HR; Wagstaff GF Psychopharmacology (Berl); 2002 Jul; 162(2):215-7; discussion 218-22. PubMed ID: 12110999 [No Abstract] [Full Text] [Related]
18. [Effects of ecstasy on the body]. Saarijärvi S; Lopperi M Duodecim; 2003; 119(13):1211-5. PubMed ID: 12908183 [No Abstract] [Full Text] [Related]
19. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users. Parrott A Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401 [No Abstract] [Full Text] [Related]
20. [Ecstasy, a new designer drug in the techno-scene]. Kuhlmann T Psychiatr Prax; 1996 Nov; 23(6):266-9. PubMed ID: 9036394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]